B7 Costimulation and Intracellular Indoleamine 2,3-Dioxygenase Expression in Umbilical Cord Blood and Adult Peripheral Blood  by Grozdics, Enikő et al.
E. Grozdics et al. / Biol Blood Marrow Transplant 20 (2014) 1641e1665 165913. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective
therapy for antibody- and cell-mediated acute rejection. Trans-
plantation. 2008;86:1754-1761.
14. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-
speciﬁc anti-human leukocyte antigen antibodies and reversal of
antibody-mediated rejection with bortezomib in pediatric heart
transplant patients. Transplantation. 2012;93:319-324.
15. Raghavan R, Jeroudi A, Achkar K, et al. Bortezomib in kidney trans-
plantation. J Transplant. 2010. Available at: http://dx.doi.org/10.1155/
2010/698594.
16. Sadaka B, Alloway RR, Woodle ES. Clinical and investigational use of
proteasome inhibitors for transplant rejection. Exp Opin Invest Drugs.
2011;20:1535-1542.
17. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies
via proteasome inhibition. Transplantation. 2009;87:1555-1561.
18. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary
therapy for antibody-mediated renal allograft rejection. Trans-
plantation. 2010;89:277-284.Financial disclosure: See Acknowledgments on page 1664.
* Correspondence and reprint requests: Gergely Toldi, MD, PhD, First
Department of Pediatrics, Semmelweis University, Budapest, Bókay u.
53-54, H-1083, Hungary.
E-mail address: toldigergely@yahoo.com (G. Toldi).
1083-8791/$ e see front matter  2014 American Society for Blood and
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2014.06.00819. Woodle ES, Alloway RR, Girnita A. Proteasome inhibitor treatment of
antibody-mediated allograft rejection. Curr Opin Organ Transplant.
2011;16:434-438.
20. Woodle ES, Walsh RC, Alloway RR, et al. Proteasome inhibitor therapy
for antibody-mediated rejection. Pediatr Transplant. 2011;15:548-556.
21. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intrave-
nous administration of bortezomib in patients with relapsed multiple
myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol.
2011;12:431-440.
22. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development:
from B-cell subsets to long-term survival niches. Semin Immunol. 2008;
20:49-58.
23. Everly MJ, Terasaki PI, Hopﬁeld J, et al. Protective immunity remains
intact after antibody removal by means of proteasome inhibition.
Transplantation. 2010;90:1493-1498.
24. Reardon JE, Marques MB. Laboratory evaluation and transfusion sup-
port of patients with autoimmune hemolytic anemia. Am J Clin Pathol.
2006;125(Suppl):S71-S77.B7 Costimulation and Intracellular Indoleamine
2,3-Dioxygenase Expression in Umbilical Cord Blood and Adult
Peripheral Blood
Enik}o Grozdics 1,2, László Berta 1,2, Béla Gyarmati 3, Gábor Veres 4, Dénes Zádori 4,
Levente Szalárdy 4, László Vécsei 4,5, Tivadar Tulassay 1,2, Gergely Toldi 1,2,*
1 First Department of Pediatrics, Semmelweis University, Budapest, Hungary
2MTA-SE Pediatrics and Nephrology Research Group, Budapest, Hungary
3Department of Obstetrics and Gynecology, Uzsoki Street Hospital, Budapest, Hungary
4Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
5MTA-SZTE Neuroscience Research Group, Szeged, HungaryArticle history:
Received 6 January 2014
Accepted 5 June 2014
Key Words:
B7
CD28
Indoleamine 2,3-dioxygenase
Kynurenine
Monocyte
T cell
Tryptophana b s t r a c t
Alterations in the expression of B7 costimulatory molecules and their receptors, as well as differences in the
tryptophan (TRP) catabolic pathway, may inﬂuence immunological reactivity of umbilical cord blood (UCB)
compared with adult peripheral blood (APB) T lymphocytes. We determined the frequency of activated
(CD11bþ) monocytes expressing B7-1, B7-2, B7-H1, and B7-H2, and that of T cells and CD4þ T helper cells
expressing CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death-1 receptor, and inducible
costimulator of T cells in UCB and APB samples using ﬂow cytometry. We also examined the intracellular
expression of indoleamine 2,3-dioxygenase (IDO) applying ﬂow cytometry and plasma levels of TRP,
kynurenine (KYN), and kynurenic acid using high-performance liquid chromatography. The level of CTLA-4
expression on CD4 cells was higher in UCB compared with in APB, indicating that the possibility of CD28-
mediated costimulation may be decreased. The level of the corresponding costimulator molecule, B7-2,
was also elevated. Therefore, this inhibitory relation may function to a higher extent in UCB than in APB.
The plasma KYN to TRP (K/T) ratio was 2-fold higher in UCB compared with APB. However, the capacity of
UCB monocytes to produce IDO compared with APB monocytes was lower, and reverse signaling via B7-2 in
UCB monocytes was found to be immature, which suggests that the observed increase in K/T ratio may be due
to placental, rather than fetal, overexpression of IDO in competent cells. These factors may all contribute to
the previously observed reduced reactivity of UCB T lymphocytes compared to APB T cells.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Antigen presentation and costimulation are the initial
steps in adequate T cell function and play an important rolein the coordination of downstream events in immune re-
sponse. Alterations in the expression of costimulatory mol-
ecules and receptors may inﬂuence differences observed
between immunological reactivity of umbilical cord blood
(UCB) and adult peripheral blood (APB) T lymphocytes.
B7 costimulatory molecules are expressed on antigen-
presenting cells (APCs) and are important regulators of T
cell activation (Table 1). Upon the engagement of the T cell
receptor (TCR), the costimulatory signal from B7-1 (CD80) or
B7-2 (CD86) via CD28 induces the production of IL-2 in T
cells, thus protecting them from apoptosis and anergy. Both
the TCR and CD28 are constitutively expressed bymost naïve
Table 1
The Investigated B7 Family Proteins on Antigen-Presenting Cells and Their
Receptors on T Cells
APC T Cell Effect on T Cell
B7-1 (CD80) CD28 Stimulation
CTLA-4 (CD152) Inhibition
B7-2 (CD86) CD28 Stimulation
CTLA-4 (CD152) Inhibition
B7-H1 (CD274) PD-1 (CD279) Inhibition
B7-H2 (CD275) ICOS (CD278) Stimulation
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sented [1]. Without costimulation, the signal from the TCR
induces the tolerance of T cells to their cognate antigen,
instead of being activated [2].
Nevertheless, B7 family members mediate not only stim-
ulatory but also inhibitory effects on T cells and, therefore,
may contribute to the lower reactivity of UCB T lymphocytes
comparedwith those of APB [1]. Upon the stimulation of TCR,
cytotoxic T lymphocyte antigen 4 (CTLA-4, CD152) becomes
phosphorylated, resulting in its stabilization on the cell sur-
face. Thisway, CTLA-4 can competewith CD28 for B7 binding,
thus blocking the costimulatory signal and preventing IL-2
production. The afﬁnity of the inhibitory receptor, CTLA-4,
is higher than that of CD28 for B7-1 and B7-2. Besides its
competitive role, CTLA-4 further emits inhibitory signals,
thus contributing to the prevention of T cell activation [3].
Another B7 family member, B7-H1 (CD274) possesses
mostly, but not exclusively, inhibitory properties on T cells. Its
inhibitory function occurs by signaling through the pro-
grammed death-1 receptor (PD-1, CD279), inducing apoptosis
or anergy of self-reactive T cells [4]. Genetic deletion of PD-1
results in severe autoimmunity due to the loss of peripheral
tolerance of self-reactive T cells [5].
B7-H2 (CD275) serves as the ligand for inducible cos-
timulator of T cells (ICOS, CD278), and promotes T cell acti-
vation, differentiation, and effector responses [6]. In contrast
to the costimulatory effect of CD28, ICOS most effectively
induces IL-10, but it does not inﬂuence IL-2 production [7].
ICOS also stabilizes IL-10R expression on T cells, increasing
their sensitivity to IL-10 [8]. Thus, the B7-H2/ICOS pathway
preferentially regulates the effector function of T cells [9].
Besides initiating signal transduction in T lymphocytes,
B7-1 and B7-2 may back-signal into the APC and inﬂuence
the local immune environment through induced expression
of immunosuppressive factors, independent of their effects
on T cells [1]. For instance, reverse signaling through B7-1
and B7-2 after ligation by a soluble form of CTLA-4 was
shown to upregulate the tryptophan (TRP) catabolic enzyme,
indoleamine 2,3-dioxygenase (IDO) [10]. The potent immu-
nosuppressive activity of IDO was ﬁrst identiﬁed in preg-
nancy, when it was demonstrated that inhibition of IDO
activity abolished allogeneic gestation in mice [11]. In the
ﬁrst steps of the kynurenine (KYN) pathway, the rate-
limiting step in KYN formation from TRP is mediated by
IDO. KYN is then further metabolized by different enzymes.
One of them is kynurenine aminotransferase, leading to the
production of kynurenic acid (KYNA), a broad-spectrum
endogenous antagonist of excitatory amino acid receptors
[12,13], with emerging recent implications in immunomo-
dulation [14,15]. The rate of TRP degradation, represented by
the KYN to TRP ratio (K/T), allows a good estimate of IDO
activity. The local depletion of TRP and the production of
proapoptotic TRP metabolites of the KYN pathway, such as 3-hydroxyanthranilic acid and quinolinic acid, are among the
mechanisms potentially responsible for the immunosup-
pressive effects related to IDO, as reviewed by Mándi and
Vécsei [14]. As the TRP metabolic pathway is activated by
proinﬂammatory stimuli, the anti-inﬂammatory effect of
KYN metabolites provides a feedback mechanism in modu-
lating the immune response. In contrast to other immuno-
modulatory KYN derivatives, such as 3-hydroxykinurenine
and quinolinic acid, exerting toxicity on neural elements,
KYNA is generally considered as an endogenous neuro-
protective agent [15].
In this study, we aimed to determine the frequency of
activated monocytes expressing B7-1, B7-2, B7-H1, and
B-7H2 costimulatory molecules, as well as that of T cells and
T helper cells expressing CD28, CTLA-4, PD-1, and ICOS in
UCB compared with in APB. We also examined the intracel-
lular expression of IDO in activated monocytes and T cells,
along with plasma levels of TRP, KYN, and KYNA.
MATERIAL AND METHODS
Sample Collection
Peripheral blood samples were taken from 20 healthy adults (8 women
and 12men; median age, 26.5 [interquartile range, 24 to 28]) and cord blood
samples from the umbilical vein of 17 healthy, term neonates (7 girls and 10
boys; median gestational age, 39 [interquartile range, 38 to 40] weeks;
median birth weight, 3300 [interquartile range, 3150 to 3650] grams).
Informed consent was obtained from all subjects or, in the case of neonates,
parents of subjects, and our study was reviewed and approved by an inde-
pendent ethical committee of the institution. The study was adhered to the
tenets of the most recent revision of the Declaration of Helsinki.
Peripheral Blood Mononuclear Cells Isolation
Peripheral blood mononuclear cells (PBMCs) were separated by a
standard density gradient centrifugation (Ficoll Paque, Amersham Bio-
sciences AB, Uppsala, Sweden) (25 minutes, 400g, 22C) from freshly drawn
blood collected in lithium heparin-treated tubes (BD Vacutainer, BD Bio-
sciences, San Jose, CA). Cells were kept at 80C in FBS containing 10%
DMSO until analysis. After thawing, cells were washed twice in phosphate-
buffered saline and their viability was assessed by trypan blue exclusion
(consistently >90%).
Flow Cytometry
PBMCs were stained for 30 minutes at room temperature in the dark
with PerCP-conjugated CD3 (clone number: SK7), PE Cy7-conjugated CD4
(clone number: SK3), PE-conjugated CD28 (clone number: CD28.2), APC-
conjugated CD152 (CTLA-4, clone number: L3D10), FITC-conjugated CD278
(ICOS, clone number: C398.4A), and APC-Cy7-conjugated CD279 (PD-1,
clone number: EH12.2H7) mAbs, or PerCP-conjugated CD3 (clone number:
SK7), PE Cy7-conjugated CD11b (clone number: ICRF44), APC-conjugated
CD80 (B7-1, clone number: 2D10), and PE-conjugated CD275 (B7-H2,
clone number: 2D3) mAbs, or PerCP-conjugated CD3 (clone number: SK7),
PE Cy7-conjugated CD11b (clone number: ICRF44), APC-conjugated CD86
(B7-2, clone number: IT2.2), and PE-conjugated CD274 (B7-H1, clone num-
ber: 29E.2A3) mAbs in separate tubes, respectively (BioLegend, San Diego,
CA). After washing, cells were ﬁxed with ﬁxation/permeabilization solution
and treated with permeabilization buffer according to the manufacturers’
instructions (eBioscience, San Diego, CA). They were then stained with a
mouse antihuman IDO monoclonal antibody (clone number: 1F8.2, Milli-
pore, Billerica, MA) for 30 minutes at 4C in the dark. After washing, cells
were stained with FITC-labeled goat antimouse antibody (Millipore) for
15 minutes at 4C in the dark. After washing, cells were analyzed on a BD
FACSAria ﬂow cytometer (BD Biosciences) equipped with 488 nanometer
(nm) and 633 nm excitation lasers. Data were processed using the FACSDiVa
software (BD Biosciences). A total of 100,000 cells were recorded. The
populations of lymphocytes and monocytes were gated from PBMCs ac-
cording to forward-scatter characteristics and side-scatter characteristics. As
control of FITC-labeled goat antimouse speciﬁcity staining, PBMCs were
incubated with surface antibodies and FITC-labeled goat antimouse anti-
body in the absence of mouse antihuman IDO monoclonal antibody. Gating
strategy is represented in Figure 1.
High-performance Liquid Chromatography (HPLC)
The investigated reference compounds (L-TRP, L-KYN sulfate salt, KYNA)
and zinc acetate dihydrate were purchased from Sigma-Aldrich (Saint Louis,
Figure 1. Gating strategy applied for discrimination of the investigated cell subsets in ﬂow cytometry measurements. FSC indicates forward-scatter characteristics;
SSC, side-scatter characteristics.
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Table 2
Limit of Detection and Lower Limit of Quantitation for Plasma Compounds
Determined by High-Pressure Liquid Chromatography
Compound Method Concentration
Range
LOD (nM) LLOQ (nM)
Kynurenine UV .1-5 mM 100 275
Kynurenic
acid
Fluorescence 1-100 nM 1 3.75
Tryptophan Fluorescence 5-50 mM 15 35
LOD indicates limit of detection; LLOQ, lower limit of Quantitation.
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celona, Spain), and acetic acid was purchased from VWR International
(Radnar, PA).
Plasma samples were stored at80C until analysis. Before analysis, the
samples were thawed and after a brief vortex, 300 mL of plasma sample was
“shot” onto 700 mL precipitation solvent (containing 3.57 weight/weight
percent concentration (w/w%) perchloric acid and 2.857 mM 3-nitro-L-
tyrosine as internal standard). Following that, the samples were centrifuged
at 13,000g for 10 minutes at 4C, and the supernatant was collected.
The KYN, KYNA, and TRP concentrations of the samples were quantiﬁed
based on the slightly modiﬁed method of Herve et al. [16], with an Agilent
1100 HPLC system (Agilent Technologies, Santa Clara, CA). The system was
equippedwith aﬂuorescent and aUVdetector; the formerwas applied for the
determination of KYNA and TRP, and the latter for the determination of KYN
and the internal standard. Chromatographic separations were performed on
an Onyx Monolithic C18 column, 100 mm  4.6 mm I.D. (Phenomenex Inc.,
Torrance, CA) after passage through a Hypersil ODS precolumn, 20  2.1 mm
Internal diameter, 5 mm particle size (Agilent Technologies) with a mobile
phase composition of .2 M zinc acetate/acetonitrile ¼ 95/5 (volume/volume
percent concentration) with a pH adjusted to 6.2 with glacial acetic acid,
applying isocratic elution. Theﬂow rate and the injectionvolumewere 1.5mL/
minute and 20 mL, respectively. The ﬂuorescent detector was set at excitation
and emission wavelengths of 344 nm and 398 nm, and after 3.5 minutes of
each run, the wavelengths were changed to 254 nm and 398 nm. The UV
detector was set at a wavelength of 365 nm.HPLC Method Validation
Calibration curve and linearity
Calibrants were prepared at 6 different concentration levels, from 1 nM
to 100 nM, .1 nM to 5 mM, 5 nM to 50 mM, and .5 nM to 7.5 mM, for KYNA, KYN,
TRP, and the internal standard, respectively. Three parallel injections of each
solutionwere made under the chromatographic conditions described above.
The peak area responses were plotted against the corresponding concen-
tration, and the linear regression computations were carried out by the least
square method with the freely available R software [17]. Very good linearity
was observed throughout the investigated concentration ranges for KYN,Table 3
Frequency of the Investigated Cell Surface and Intracellular Markers and Plasma Le
Cell Type
CD3þ CD28þ cells/CD3þ lymphocytes, %
CD3þ CD28þ CD152þ cells/CD3þ CD28þ lymphocytes, %
CD3þ CD278þ cells/CD3þ lymphocytes, %
CD3þ CD279þ cells/CD3þ lymphocytes, %
CD4þ CD28þ cells/CD4þ lymphocytes, %
CD4þ CD28þ CD152þ cells/CD4þ CD28þ lymphocytes, %
CD4þ CD278þ cells/CD4þ lymphocytes, %
CD4þ CD279þ cells/CD4þ lymphocytes, %
CD11bþ cells/monocytes, %
CD11bþ CD80þ cells/CD11bþ monocytes, %
CD11bþ CD86þ cells/CD11bþ monocytes, %
CD11bþ CD274þ cells/CD11bþ monocytes, %
CD11bþ CD275þ cells/CD11bþ monocytes, %
CD3þ IDOþ cells/CD3þ lymphocytes, %
IDO MFI in CD3þ IDOþ cells (arbitrary unit)
CD11bþ IDOþ cells/CD11bþ monocytes, %
IDO MFI in CD11bþ IDOþ cells (arbitrary unit)
KYN (mM)
KYNA (nM)
TRP (mM)
K/T ratio
* P < .05 versus APB. Data are presented as median (interquartile range).KYNA, TRP, and the internal standard when either ﬂuorescence or UV
detection was applied.
Selectivity
The selectivity of the method was checked by comparing the chromato-
gramsof KYN,KYNA, TRP, and the internal standard for a blankplasma sample
and those for a spiked plasma sample. All compounds could be detected in
their own selected chromatograms without any signiﬁcant interference.
Limit of detection and lower limit of quantitation
Limit of detection and lower limit of quantitation were determined via
signal-to-noise ratio with a threshold 3 and 10, according to the Interna-
tional Conference on Harmonization guidelines [18]. The limit of detection
was 100 nM, 1 nM, and 15 nM, whereas the lower limit of quantitation was
275 nM, 3.75 nM, and 35 nM for KYN, KYNA, and TRP, respectively (Table 2).
Precision
Replicate HPLC analysis showed that the relative standard deviationwas
2.2% for the peak area response and .1% for the retention time.
Recovery
The relative recoveries were estimated by measuring spiked samples of
KYN, KYNA, and TRP at 2 different concentrations with 3 replicates of each.
No signiﬁcant differences were observed for the lower and higher concen-
trations. The recoveries ranged from 108% to 110%, 86% to 91%, and 85% to
89% for KYN, KYNA, and TRP, respectively.
Statistics
Data are expressed as median and interquartile range. Comparisons
between sample populations were made with the Mann-Whitney test.
Correlation analyses were performed using Spearman tests. P values less
than .05 were considered signiﬁcant. Statistics were calculated using the
STATISTICA software (version 8.0; StatSoft, Inc., Tulsa, OK).
RESULTS
Our results are detailed in Table 3.
A statistically signiﬁcant but biologically modest decrease
in the frequency of CD4þ CD28þ lymphocytes was observed
in UCB in comparison with APB. At the same time, a more
considerable increase was noticed in the expression of the
regulatory receptor CD152 (CTLA-4) on these cells. The fre-
quency of CD11bþ CD86þmonocytes was higher in UCB than
in APB.
The prevalence of CD3þ CD278þ lymphocytes was also
higher in UCB than in APB; however, this difference was not
signiﬁcant in the CD4þ subset. The frequency of the corre-
sponding costimulatory molecule, CD275 on CD11bþvels of Kynurenine, Kynurenic Acid, and Tryptophan
APB (n ¼ 20) UCB (n ¼ 17)
77.2 (65.8-82.5) 80.7 (71.2-88.4)
8.74 (6.46-11.7) 12.0 (6.09-15.8)
56.4 (50.4-74.9) 73.6* (67.9-77.7)
51.2 (45.3-61.2) 52.7 (28.0-61.6)
97.9 (96.8-99.1) 95.4* (93.1-98.3)
6.15 (4.55-8.57) 9.21* (6.53-13.1)
59.2 (54.8-74.0) 69.4 (59.3-79.2)
54.2 (49.1-63.3) 54.5 (42.5-57.3)
80.4 (75.0-87.3) 81.0 (73.2-86.1)
54.2 (19.6-68.8) 34.0 (19.7-56.7)
27.6 (19.6-29.8) 43.1* (30.0-51.9)
74.1 (68.2-84.9) 57.2* (51.5-72.7)
61.2 (34.5-70.0) 46.6 (39.1-57.9)
3.33 (2.12-5.95) 4.57 (3.00-10.8)
9888 (7461-11,175) 7627* (6551-9768)
2.45 (1.92-2.99) % 2.90 (1.65-4.52) %
21,400 (19,075-24,175) 15,200* (13,300-18,700)
1.80 (1.63-2.26) 4.77* (3.73-5.45)
29.8 (22.9-42.8) 294.7* (253.8-360.6)
53.4 (46.3-59.6) 62.4* (56.6-70.4)
.036 (.032-.041) .075* (.063-.086)
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of CD11bþ CD274þmonocytes, providing inhibitory signal via
CD279, was lower in UCB compared with APB.
A tendency was observed for an increased prevalence of
IDO-expressing cells among CD3þ lymphocytes in UCB
compared with ABP (P ¼ .069), whereas their frequency in
the CD11bþ subset was comparable. The mean ﬂuorescence
intensity (MFI) values for IDOwere lower in UCB than in APB,
both in case of CD3þ lymphocytes and CD11bþ monocytes.
Plasma KYN and TRP levels were higher in UCB than in
APB, with a more pronounced increase in KYN, resulting in a
more than 2-fold higher K/T ratio in UCB, compared with
APB. KYNA levels were also considerably, almost 10-fold,
higher in UCB.
To explore the presence of reverse signaling via CD80 and
CD86, correlation analyses were performed. A negative cor-
relation between the frequency of CD11bþ CD86þmonocytes
and IDO-expressing CD11bþ monocytes was found in UCB
(Spearman’s Rho ¼ .59), whereas no correlation was pre-
sent in APB. Furthermore, a positive correlationwas detected
between MFI of IDO in CD3þ cells and the prevalence of
CD11bþ CD80þ monocytes in APB (Spearman’s Rho ¼ .48).
DISCUSSION
Lower reactivity of UCB T cells in comparison to APB T
lymphocytes is a widely recognized phenomenon [19].
However, details behind this difference are not fully under-
stood. In this study, we aimed to characterize the prevalence
of B7 costimulatory molecules on monocytes and their cor-
responding receptors on T lymphocytes in UCB compared
with APB, as well as the intracellular expression of IDO and
plasma levels of TRP, KYN, and KYNA, important molecules
with immunoregulatory properties, to describe their poten-
tial contribution to lower immunological reactivity of UCB
T cells.
The minor decrease in the frequency of CD4þ CD28þ
lymphocytes and, more importantly, the higher prevalence
of CTLA-4 expressing cells within this subset, indicate that
the possibility of costimulation via CD28may be decreased in
UCB compared with APB. Whereas CD28 is constitutively
expressed on T cells, CTLA-4 is directed at the cell surface
upon the stimulation of CD28 to provide negative regulation
for CD28 signaling. CTLA-4 shows a high sequence homology
with CD28 and competes with CD28 for B7 molecules on the
APC. Upon binding, it provides a negative signal to T lym-
phocytes, which terminates the proliferative phase. As
described earlier, B7-1 and B7-2 have a higher afﬁnity for the
inhibitory receptor CTLA-4 in comparison with CD28 [3].
Because the level of CTLA-4 expression on CD4 cells is higher
in UCB, and at the same time that of B7-2 levels are also
elevated, this inhibitory relation may function to a higher
extent in UCB in comparison with APB. Further functional
analyses are needed to conﬁrm or refute this hypothesis. On
the other hand, the higher expression of CTLA-4 on UCB T
cells might be the consequence of the higher level of antigen
presentation, which is a characteristic feature of immune
response at this early stage of life. In a study by Han et al.,
UCB monocytes were characterized by low baseline expres-
sion of the costimulatory molecules B7-2 and CD40
compared with adults. Expression of these molecules was
not upregulated by potent activators, such as the combina-
tion of IFN-gamma and CD40 ligand [20]. The difference
between this ﬁnding and ours might be due to the fact that
we investigated CD11bþ-activated monocytes, exhibitingelevated B7-2 levels. This notion is reinforced by our analysis
of B7-2 expression on CD11b monocytes, indicating a
decrease in UCB compared with APB, in line with the results
of Han et al. (median, 53.1% [interquartile range, 34.3% to
65.3%] versus median, 31.3% [interquartile range, 26.6% to
44.7%]; P ¼ .004). CD11b is an integrin-type transmembrane
glycoprotein. After a noncovalent association with CD18, it
plays a crucial role in the adhesion, transendothelial migra-
tion, and thus the activation of monocytes [21]. In other in-
vestigations, UCB dendritic cells (DCs) also appeared to be
immature as they exhibited low or no basal expression of
CD40, B7-1, or B7-2 [22,23].
With regard to CD28 and CTLA-4, the ﬁndings of Elliott
et al. are contradicting ours. In their study, a higher per-
centage of resting T cells expressed CD28 in UCB and young
children compared with adults. CD28 expression was similar
on APB and UCB T cells activated with PMA and ionomycin.
Interestingly, surface CTLA-4 expression was lower on UCB
than on APB T cells stimulated with phorbol myristate
acetate and ionomycin. In contrast, intracellular CTLA-4
expression was equivalent, suggesting that trafﬁcking of
CTLA-4 to the cell surface may be differentially regulated in
UCB T cells [24].
In our study, the prevalence of CD3þ CD278þ lymphocytes
was higher in UCB than in APB. The frequency of the
corresponding costimulatory molecule, B7-H2, on CD11bþ
monocytes was comparable in the 2 groups. In contrast, that
of B7-H1eexpressing CD11bþ monocytes, providing inhibi-
tory signal via CD279, was lower in UCB compared with APB.
These ﬁndings indicate that there is a shift towards the
stimulatory from the inhibitory direction in UCB at the level
of B7-H1 and B7-H2 proteins, the signiﬁcance of which
necessitates further investigation. Darmochwal-Kolarz et al.
determined the expression of B7-H1, B7-H4, CD200, and
CD200R onmyeloid BDCA-1þ and lymphoid BDCA-2þ DCs, as
well as on monocytes and B lymphocytes in UCB, compared
with APB [25]. They revealed that the expressions of these
molecules were signiﬁcantly lower on UCB DCs compared
with adults. The lower expression of B7-H1 on UCB APCs is in
line with our ﬁndings.
IDO is a key enzyme in the catabolism of TRP and initiates
the production of KYN. These metabolites have several
immunological and nonimmunological regulatory functions.
By locally depleting TRP and increasing the levels of KYN and
its metabolites, IDO provides a suppression of T cellemedi-
ated immune response via inhibiting the proliferation and
inducing the apoptosis of activated T cells, as well as pro-
moting the development of regulatory T cells and tolerogenic
DCs [26]. In our study, we found that the plasma K/T ratio, a
formula generally used as an estimated representation of the
enzymatic activity of IDO, is 2-fold higher in UCB compared
with APB. Unlike cellular components, both KYNand TRPmay
readily cross the placenta, similar to other biological barriers,
such as the blood brain barrier [27] and enter the fetal circu-
lation from the maternal circulation. Therefore, the observed
increase in K/T ratio in UCB may well reﬂect the previously
reported increased placental IDO activity, providing mater-
nofetal immunological tolerance [1,28]. This elevation in K/T
ratiomight be an important regulatory factor that contributes
to lower reactivity of UCB T lymphocytes. Furthermore, we
found that the transformation of KYN toKYNA is also elevated
in UCB compared with APB, resulting in a 10-fold elevation of
the plasma level of the anti-inﬂammatory KYNA [14], which
may indicate the presence and high activity of organic acid
E. Grozdics et al. / Biol Blood Marrow Transplant 20 (2014) 1641e16651664transporters in the placental barrier; however, the increased
activity of kynurenine aminotransferase enzyme in the
competent cells cannot be fully excluded either.
The engagement of B7-1 and B7-2 by CTLA-4 induces
back signaling into the monocyte and promotes the pro-
duction of IFN-gamma, which acts in an autocrine or para-
crine manner to induce IDO expression, thereby initiating
the degradation of TRP and resulting in an immunosup-
pressive effect, as described above. Thus, the interaction
between CTLA-4 and B7 proteins plays 2 different roles:
ﬁrst, at the level of T cells, where CTLA-4 as a negative re-
ceptor regulates TCR signal transduction; second, at the
level of APCs, where CTLA-4 as a ligand signals to the APC to
induce IDO expression [9]. Based on the higher frequency of
CTLA-4eexpressing CD4þ CD28þ lymphocytes in UCB, we
hypothesized that reverse signaling may be increased in
UCB. However, detailed analyses did not support this notion.
Indeed, the frequency of IDO-expressing CD11bþ monocytes
was comparable in UCB and APB. Furthermore, MFI values
for IDO were lower in UCB than in APB in CD11bþ mono-
cytes. This might indicate a lower capacity of UCB cells to
produce IDO and that reverse signaling in CD11bþ cells may
not be mature in UCB. This ﬁnding strengthens our hy-
pothesis that the elevated K/T ratio observed in UCB may
reﬂect placental (or maternal) IDO activation rather than the
effect of IDO-competent APCs in UCB. In our earlier inves-
tigation, we demonstrated a positive correlation between
IDO and B7-2 expression in activated monocytes in preg-
nancy [28]. Although this correlation could not be observed
in our current study in APB, probably because of the limited
sample size, the presence of a negative correlation between
IDO and B7-2 expression in activated monocytes in UCB
might also reﬂect that reverse signaling via B7-2 is imma-
ture in UCB.
In this study, we identiﬁed 3 factors that may contribute
to the previously observed reduced reactivity of UCB
compared with APB lymphocytes. First, the level of CTLA-4
expression on CD4 cells was higher in UCB compared with
APB, indicating that the possibility of CD28-mediated cos-
timulation may be decreased. At the same time, we found
that the level of the corresponding costimulator molecule,
B7-2, is also elevated. Therefore, this inhibitory relation may
function to a higher extent in UCB in comparison with APB.
Second, the plasma K/T ratio is 2-fold higher in UCB
compared with APB, which corresponds to earlier ﬁndings of
increased placental IDO activity in favor of an immunosup-
pressive milieu providing maternofetal tolerance, and may
contribute to the decreased reactivity of T cells in UCB.
Interestingly, the level of anti-inﬂammatory KYNA is also
considerably higher, almost 10-fold, in UCB, which may
indicate the presence and high activity of organic acid
transporters in the placental barrier. Finally, to our knowl-
edge, this is the ﬁrst report describing a lower capacity of
UCB compared with APBmonocytes to produce IDO, and that
reverse signaling in UCB monocytes may not be mature,
which suggests that the observed increase in K/T ratio may
be due to placental, rather than fetal, overexpression of IDO
in competent cells. Our study also detected a shift towards
the stimulatory, from the inhibitory, direction in UCB at the
level of B7-H1 and B7-H2 proteins, the biological signiﬁcance
of which is yet to be established.
Further investigations aimed at the above target mole-
cules andmechanisms are needed to providemore details on
the functional importance and clinical relevance of our
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